Fully Human Antibody Immunoglobulin from Transchromosomic Bovines is Potent Against SARS-CoV-2 Variant Pseudoviruses
Preprint
- 9 August 2021
- preprint
- research article
- Published by Cold Spring Harbor Laboratory
Abstract
SAB-185 is a fully human polyclonal anti-SARS-CoV-2 immunoglobulin produced from the plasma of transchromosomic bovines that are hyperimmunized with recombinant SARS-CoV-2 Wuhan-Hu-1 Spike protein. SAB-185 is being evaluated for efficacy in aphase 3 clinical trial. The World Health Organization (WHO) has identified multiple Variants-of-Concern and Variants-of-Interest (VOC/VOI) that have mutations in their Spike protein that appear to increase transmissibility and/or reduce the effectiveness of therapeutics and vaccines, among other parameters of concern. SAB-185 was evaluated using lentiviral-based pseudovirus assays performed in a BSL2 environment that incorporates stable or transient cell lines that express human angiotensin converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2). The results indicate that SAB-185 retained neutralization potency against multiple SARS-CoV-2 pseudovirus variants, including the Delta, Kappa, Lambda and Omicron variants, that have or are supplanting other VOC/VOI in many countries and regions around the world.Keywords
This publication has 11 references indexed in Scilit:
- Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodiesNature, 2021
- Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluationScientific Reports, 2021
- Key substitutions in the spike protein of SARS-CoV-2 variants can predict resistance to monoclonal antibodies, but other substitutions can modify the effectsPublished by Cold Spring Harbor Laboratory ,2021
- Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralizationNature, 2021
- Human immunoglobulin from transchromosomic bovines hyperimmunized with SARS-CoV-2 spike antigen efficiently neutralizes viral variantsHuman Vaccines & Immunotherapeutics, 2021
- Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19Cell Reports, 2021
- Immune Evasion of SARS-CoV-2 Emerging Variants: What Have We Learnt So Far?Viruses, 2021
- SARS-CoV-2 B.1.617.2 Delta variant replication, sensitivity to neutralising antibodies and vaccine breakthroughPublished by Cold Spring Harbor Laboratory ,2021
- Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2PLOS ONE, 2021
- A pneumonia outbreak associated with a new coronavirus of probable bat originNature, 2020